EHA 2020: A paradigm shift for the treatment of newly diagnosed older acute myeloid leukaemia patients

Pinterest LinkedIn Tumblr +

Acute myeloid leukaemia (AML) is primarily a disease of older adults.

Standard commonly utilised lower-intensity therapies, such as azacitidine or decitabine, provide only limited responses with expected median survival of 9-10 months and complete remission (CR) / CR with incomplete count recovery (CRi) rates <40%.

We evaluated the efficacy of a combination regimen of azacitidine and venetoclax in treatment-naïve AML patients that were ineligible for intensive therapy.

In a Phase III randomised double-blinded multi-centre trial called “VIALE-A”, the efficacy of the combination regimen was compared to treatment with azacytidine plus a placebo.

In 431 internationally enrolled patients in the VIALE-A trial, the combination of azacitidine and venetoclax led to improved overall survival (14.7 vs 9.6 months), and improved response rates CR/CRi (66% vs 28%), compared to azacitidine alone.

In addition, the combination was associated with responses that occurred more quickly (median time to CR/CRi was only 1.3 months) and were more durable (lasting 1.5 years), and with increased incidence of transfusion independence (58% vs 34%).

In conclusion, this practice-changing multi-centre randomised Phase III trial establishes venetoclax and azacitidine as a new standard of care for older patients with AML.

Source: EHA


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.